VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

EMBO Molecular Medicine

Volumn 5, Issue 10, 2013, Pages 1569-1585

  Heier, Christopher R ^a   Damsker, Jesse M ^b   Yu, Qing ^a   Dillingham, Blythe C ^a,b   Huynh, Tony ^a,c   Van der Meulen, Jack H ^a   Sali, Arpana ^a   Miller, Brittany K ^a   Phadke, Aditi ^a   Scheffer, Luana ^a   Quinn, James ^a   Tatem, Kathleen ^a   Jordan, Sarah ^a   Dadgar, Sherry ^a,g   Rodriguez, Olga C ^d,e   Albanese, Chris ^d,e   Calhoun, Michael ^f   Gordish Dressman, Heather ^a,g   Jaiswal, Jyoti K ^a,g   Connor, Edward M ^a,b   Mccall, John M ^b,h   Hoffman, Eric P ^a,b,g   Reeves, Erica K M ^b   Nagaraju, Kanneboyina ^a,b,g   more..

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b ReveraGen Biopharma   (United States)

^c CANBERRA HOSPITAL   (Australia)

^d GEORGETOWN UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f Sinq Systems Inc   (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h PharMac LLC   (United States)

Author keywords

Anti inflammatory; Dystrophy; mdx; Membrane injury; Muscle

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VBP 15;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE GROWTH; CHRONIC DISEASE; CONTROLLED STUDY; DRUG MECHANISM; INFLAMMATORY DISEASE; MOUSE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NEWBORN SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SKELETAL MUSCLE;

ANTI-INFLAMMATORY; DYSTROPHY; MDX; MEMBRANE INJURY; MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL MEMBRANE; IMMUNOSUPPRESSIVE AGENTS; LASERS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; MYOBLASTS; NECROSIS; NF-KAPPA B; PHENOTYPE; PREDNISOLONE; PREGNADIENEDIOLS; PROTEIN INTERACTION MAPS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84884938319     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201302621     Document Type: Article

References (78)

1. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18: 1995-2005
2. Avioli LV (1993) Glucocorticoid effects on statural growth. Br J Rheumatol 32: 27-30
3. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168-172
4. Baudy AR, Saxena N, Gordish H, Hoffman EP, Nagaraju K (2009) A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int Immunopharmacol 9: 1209-1214
5. Baudy AR, Sali A, Jordan S, Kesari A, Johnston HK, Hoffman EP, Nagaraju K (2011) Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol Imaging Biol 13: 462-470
6. Baudy AR, Reeves EK, Damsker JM, Heier C, Garvin LM, Dillingham BC, McCall J, Rayavarapu S, Wang Z, Vandermeulen JH, et al (2012) Delta-9, 11 modification of glucocorticoids dissociates nuclear factor-kappaB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther 343: 225-232
7. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11: 463-471
8. Bazan NG, Marcheselli VL, Cole-Edwards K (2005) Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci 1053: 137-147
9. Bertorini TE, Bhattacharya SK, Palmieri GM, Chesney CM, Pifer D, Baker B (1982) Muscle calcium and magnesium content in Duchenne muscular dystrophy. Neurology 32: 1088-1092
10. Bircan Z, Soran M, Yildirim I, Dogan M, Sahin A, Bilici A, Danaci M (1997) The effect of alternate-day low dose prednisolone on bone age in children with steroid dependent nephrotic syndrome. Int Urol Nephrol 29: 357-361
11. Brooks SV, Faulkner JA (1988) Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 404: 71-82
12. Burkin DJ, Wuebbles RD (2012) A molecular bandage for diseased muscle. Sci Transl Med 4: 139fs119
13. Buttgereit F, Brand MD, Burmester GR (1999) Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 58: 363-368
14. Cai D, Frantz JD, Tawa NE, Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298
15. Chase TH, Cox GA, Burzenski L, Foreman O, Shultz LD (2009) Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B. Am J Pathol 175: 2299-2308
16. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65: 826-834
17. Dahlman-Wright K, Wright A, Gustafsson JA, Carlstedt-Duke J (1991) Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. J Biol Chem 266: 3107-3112
18. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727
19. Delfin DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM (2011) Improvement of cardiac contractile function by peptide-based inhibition of NF-kappaB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med 9: 68
20. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR (1990) Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249: 1266-1272
21. Disatnik MH, Dhawan J, Yu Y, Beal MF, Whirl MM, Franco AA, Rando TA (1998) Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. J Neurol Sci 161: 77-84
22. Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, Schmidt TJ (1993) Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J 12: 145-156
23. Dumonceaux J, Marie S, Beley C, Trollet C, Vignaud A, Ferry A, Butler-Browne G, Garcia L (2010) Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther 18: 881-887
24. Gajic O, Lee J, Doerr CH, Berrios JC, Myers JL, Hubmayr RD (2003) Ventilator-induced cell wounding and repair in the intact lung. Am J Respir Crit Care Med 167: 1057-1063
25. Gehrig SM, van der Poel C, Sayer TA, Schertzer JD, Henstridge DC, Church JE, Lamon S, Russell AP, Davies KE, Febbraio MA, et al (2012) Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 484: 394-398
26. Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD, Davies KE (2010) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18: 198-205
27. Grady RM, Merlie JP, Sanes JR (1997a) Subtle neuromuscular defects in utrophin-deficient mice. J Cell Biol 136: 871-882
28. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR (1997b) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90: 729-738
29. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR (1999) Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1: 215-220
30. Granchelli JA, Avosso DL, Hudecki MS, Pollina C (1996) Cromolyn increases strength in exercised mdx mice. Res Commun Mol Pathol Pharmacol 91: 287-296
31. Griggs RC, Moxley RT, III, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, et al (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43: 520-527
32. Grounds MD, Shavlakadze T (2011) Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. Bioessays 33: 458-468
33. Grounds MD, Torrisi J (2004) Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18: 676-682
34. Guo C, Willem M, Werner A, Raivich G, Emerson M, Neyses L, Mayer U (2006) Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 15: 989-998
35. Heine VM, Rowitch DH (2009) Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J Clin Invest 119: 267-277
36. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, Connor EM (2011) Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 179: 12-22
37. Housley PR, Forsthoefel AM (1989) Isolation and characterization of a mouse L cell variant deficient in glucocorticoid receptors. Biochem Biophys Res Commun 164: 480-487
38. Howard AC, McNeil AK, McNeil PL (2011) Promotion of plasma membrane repair by vitamin E. Nat Commun 2: 597
39. Itani OA, Liu KZ, Cornish KL, Campbell JR, Thomas CP (2002) Glucocorticoids stimulate human sgk1 gene expression by activation of a GRE in its 5′-flanking region. Am J Physiol Endocrinol Metab 283: E971-E979
40. Jaiswal JK, Marlow G, Summerill G, Mahjneh I, Mueller S, Hill M, Miyake K, Haase H, Anderson LV, Richard I, et al (2007) Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. Traffic 8: 77-88
41. Johnsen SD (2001) Prednisone therapy in Becker's muscular dystrophy. J Child Neurol 16: 870-871
42. Kar NC, Pearson CM (1978) Muscular dystrophy and activation of proteinases. Muscle Nerve 1: 308-313
43. Kavanagh RJ, Kam PC (2001) Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 86: 110-119
44. Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT, III, Cwik VA, Brooke MH, Mendell JR (1993) Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 43: 532-536
45. Knuesel I, Riban V, Zuellig RA, Schaub MC, Grady RM, Sanes JR, Fritschy JM (2002) Increased vulnerability to kainate-induced seizures in utrophin-knockout mice. Eur J Neurosci 15: 1474-1484
46. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, et al (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191
47. Lipworth BJ (2000) Therapeutic implications of non-genomic glucocorticoid activity. Lancet 356: 87-89
48. Manolagas SC, Weinstein RS (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 1061-1066
49. Marques MJ, Ventura Machado R, Minatel E, Santo Neto H (2008) Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. Muscle Nerve 37: 61-67
50. Megeney LA, Kablar B, Perry RL, Ying C, May L, Rudnicki MA (1999) Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 96: 220-225
51. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR (2009) DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324: 407-410
52. Mourkioti F, Kratsios P, Luedde T, Song YH, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M, Rosenthal N (2006) Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 116: 2945-2954
53. Nagaraju K, Willmann R (2009) Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zurich, June 30th-July 1st 2008. Neuromuscul Disord 19: 502-506
54. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfin DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, et al (2011) Peptide-based inhibition of NF-kappaB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 17: 508-515
55. Pinsky L, Digeorge AM (1965) Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science 147: 402-403
56. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Guo W, Andrade FH (2002) A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11: 263-272
57. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S (2003) Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 12: 1813-1821
58. Rando TA, Disatnik MH, Yu Y, Franco A (1998) Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 8: 14-21
59. Raymackers JM, Debaix H, Colson-Van Schoor M, De Backer F, Tajeddine N, Schwaller B, Gailly P, Gillis JM (2003) Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant. Neuromuscul Disord 13: 376-387
60. Reeves EK, Hoffman EP, Nagaraju K, Damsker JM, McCall JM (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9, 11 steroid. Bioorg Med Chem 21: 2241-2249
61. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, et al (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531-541
62. Rhen T, Grissom S, Afshari C, Cidlowski JA (2003) Dexamethasone blocks the rapid biological effects of 17beta-estradiol in the rat uterus without antagonizing its global genomic actions. FASEB J 17: 1849-1870
63. Saija A, Tomaino A, Pellegrino ML, Giuffrida N, Trombetta D, Castelli F (2001) In vitro evaluation of the antioxidant activity and biomembrane interaction of the lazaroid U-74389G. Life Sci 68: 1351-1366
64. Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP, Nagaraju K (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS ONE 7: e34204
65. Sharma N, Medikayala S, Defour A, Rayavarapu S, Brown KJ, Hathout Y, Jaiswal JK (2012) Use of quantitative membrane proteomics identifies a novel role of mitochondria in healing injured muscles. J Biol Chem 287: 30455-30467
66. Shivaji S, Jagannadham MV (1992) Steroid-induced perturbations of membranes and its relevance to sperm acrosome reaction. Biochim Biophys Acta 1108: 99-109
67. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, et al (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602
68. Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, Nagaraju K (2011) Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 11: 20
69. Takeda A, Jimi T, Wakayama Y, Misugi N, Miyake S, Kumagai T (1992) Demonstration of cathepsins B, H and L in xenografts of normal and Duchenne-muscular-dystrophy muscles transplanted into nude mice. Biochem J 288: 643-648
70. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM (2010) Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 120: 1140-1150
71. Wakefield PM, Tinsley JM, Wood MJ, Gilbert R, Karpati G, Davies KE (2000) Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther 7: 201-204
72. Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, Tan T, Ferrante C, Zhu H, Chen PJ, et al (2012) Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 4: 139ra185
73. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA (2009) Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19: 241-249
74. Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM, Nagaraju K (2012) Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 22: 43-449
75. Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der Burg B, Baeuerle PA, van der Saag PT (1997) Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem 272: 22278-22284
76. Wolthers OD, Pedersen S (1990) Short term linear growth in asthmatic children during treatment with prednisolone. BMJ 301: 145-148
77. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM (2005) Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436: 1025-1029
78. Yoshiuchi I, Shingu R, Nakajima H, Hamaguchi T, Horikawa Y, Yamasaki T, Oue T, Ono A, Miyagawa JI, Namba M, et al (1998) Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 83: 1016-1019